{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:02:09Z","timestamp":1770750129960,"version":"3.50.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,26]]},"DOI":"10.7759\/cureus.34235","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T17:56:20Z","timestamp":1674755780000},"source":"Crossref","is-referenced-by-count":1,"title":["Dermatomyositis With Dual Positive Anti-melanoma Differentiation-Associated Gene 5 and Anti-Sjogren Syndrome-Related Antigen 52 kD Antibodies: A Case Report and Literature Review on Clinical Characteristics"],"prefix":"10.7759","author":[{"given":"Guru Prasad","family":"Parthiban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sowbharnika","family":"Arivazhagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva Charan","family":"Anaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan","volume":"45","author":"Furst DE","year":"2012","unstructured":"Furst DE, Amato AA, Iorga \u015eR, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012, 45:676-83. 10.1002\/mus.23302","journal-title":"Muscle Nerve"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-018-0084-9","article-title":"Bench to bedside review of myositis autoantibodies","volume":"16","author":"Palterer B","year":"2018","unstructured":"Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018, 16:5. 10.1186\/s12948-018-0084-9","journal-title":"Clin Mol Allergy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta P","year":"2021","unstructured":"Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021, 41:1021-36. 10.1007\/s00296-021-04819-1","journal-title":"Rheumatol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel A","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021, 12:773352. 10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04897-1","article-title":"Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study","volume":"42","author":"Dunga SK","year":"2022","unstructured":"Dunga SK, Kavadichanda C, Gupta L, Naveen R, Agarwal V, Negi VS. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study. Rheumatol Int. 2022, 42:1155-65. 10.1007\/s00296-021-04897-1","journal-title":"Rheumatol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh S","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019, 78:988-95. 10.1136\/annrheumdis-2018-215004","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu A","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, et al.. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021, 60:3343-51. 10.1093\/rheumatology\/keaa786","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing X","year":"2020","unstructured":"Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med. 2020, 172:106134. 10.1016\/j.rmed.2020.106134","journal-title":"Respir Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1516-18","article-title":"Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis","volume":"58","author":"Sakamoto N","year":"2019","unstructured":"Sakamoto N, Ishimoto H, Nakashima S, et al.. Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis. Intern Med. 2019, 58:837-41. 10.2169\/internalmedicine.1516-18","journal-title":"Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino D","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011, 65:25-34. 10.1016\/j.jaad.2010.09.016","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010436","article-title":"Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report","volume":"97","author":"Endo Y","year":"2018","unstructured":"Endo Y, Koga T, Suzuki T, et al.. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report. Medicine (Baltimore). 2018, 97:e0436. 10.1097\/MD.0000000000010436","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino K","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010, 49:1726-33. 10.1093\/rheumatology\/keq153","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12528","article-title":"Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features","volume":"45","author":"Yasin SA","year":"2019","unstructured":"Yasin SA, Schutz PW, Deakin CT, et al.. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol. 2019, 45:495-512. 10.1111\/nan.12528","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi M","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, et al.. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020, 59:3284-92. 10.1093\/rheumatology\/keaa123","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen Z","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019, 381:291-3. 10.1056\/NEJMc1900045","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131917-dermatomyositis-with-dual-positive-anti-melanoma-differentiation-associated-gene-5-and-anti-sjogren-syndrome-related-antigen-52-kd-antibodies-a-case-report-and-literature-review-on-clinical-characteristics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:38Z","timestamp":1707508658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131917-dermatomyositis-with-dual-positive-anti-melanoma-differentiation-associated-gene-5-and-anti-sjogren-syndrome-related-antigen-52-kd-antibodies-a-case-report-and-literature-review-on-clinical-characteristics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.34235","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}